Abrao, Mauricio S.

No ORCID on file · 9 papers in corpus · active 2011-2021

Study types

  • article 5
  • other 4

Condition tags

  • endometriosis 9
  • dyspareunia 4
  • dysmenorrhea 2
  • die_deep_infiltrating 1
article 2021
·doi:10.6084/m9.figshare.14795093

Additional file 1: Supplemental Table 1. Endometriosis Health Profile-30 at month 3 – pain; Supplemental Table 2. Endometriosis Health Profile-30 at month 3 – control and powerlessness; Supplemental Table 3. Endometriosis Health Profile-30 …

article 2021
·doi:10.6084/m9.figshare.14795093.v1

Additional file 1: Supplemental Table 1. Endometriosis Health Profile-30 at month 3 – pain; Supplemental Table 2. Endometriosis Health Profile-30 at month 3 – control and powerlessness; Supplemental Table 3. Endometriosis Health Profile-30 …

other 2021
·doi:10.6084/m9.figshare.c.5470895

Abstract Background Elagolix is an oral, gonadotropin-releasing hormone (GnRH) receptor antagonist, that significantly reduces dysmenorrhea and non-menstrual pelvic pain (NMPP) in women with moderate to severe endometriosis-associated pain.…

other 2021
·doi:10.6084/m9.figshare.c.5470895.v1

Abstract Background Elagolix is an oral, gonadotropin-releasing hormone (GnRH) receptor antagonist, that significantly reduces dysmenorrhea and non-menstrual pelvic pain (NMPP) in women with moderate to severe endometriosis-associated pain.…

other 2019
·doi:10.25384/sage.c.4669736

Objectives:The objective was to evaluate the effects of elagolix on dyspareunia in women with endometriosis-associated pain.Methods:Data were pooled from two similar, randomized, double-blind, placebo-controlled, 6-month phase 3 studies (El…

other 2019
·doi:10.25384/sage.c.4669736.v1

Objectives:The objective was to evaluate the effects of elagolix on dyspareunia in women with endometriosis-associated pain.Methods:Data were pooled from two similar, randomized, double-blind, placebo-controlled, 6-month phase 3 studies (El…

article 2019
·doi:10.25384/sage.9873749.v1

Supplemental material, Leyland_EMph3_Dysp_appendix_revision_1July2019 for Elagolix reduced dyspareunia and improved health-related quality of life in premenopausal women with endometriosis-associated pain by Nicholas Leyland, Hugh S Taylor,…

article 2019
·doi:10.25384/sage.9873749

Supplemental material, Leyland_EMph3_Dysp_appendix_revision_1July2019 for Elagolix reduced dyspareunia and improved health-related quality of life in premenopausal women with endometriosis-associated pain by Nicholas Leyland, Hugh S Taylor,…

article 2011